Antigens, Tumor-Associated, Carbohydrate
-
Subject Areas on Research
- CA 125 in peritoneal fluid and serum from patients with benign gynecologic conditions and ovarian cancer.
- CA 125 levels in patients with ovarian carcinoma undergoing autologous bone marrow transplantation.
- Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses.
- Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer.
- Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen.
- DU-PAN-2 levels in serum and pancreatic ductal fluids of patients with benign and malignant pancreatic disease.
- Effect of radioiodination on the binding of monoclonal antibody DF3 to breast carcinoma cells.
- Elevation of multiple serum markers in patients with stage I ovarian cancer.
- Heterogeneity of antigen expression in advanced epithelial ovarian cancer.
- High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer.
- Immunohistochemical expression of CA 125 in endometrial adenocarcinoma: correlation of antigen expression with metastatic potential.
- Immunohistochemical expression of monoclonal antibody 43-9F in testicular germ cell tumours.
- Increased serum levels of macrophage colony-stimulating factor in ovarian cancer.
- Influence of circulating antigen on blood pool activity of a radioiodinated monoclonal antibody.
- Intraperitoneal cisplatin and regional hyperthermia for ovarian carcinoma.
- Involvement of histo-blood-group antigens in the susceptibility of colon carcinoma cells to natural killer-mediated cytotoxicity.
- Metastatic behavior and cell surface properties of HT-29 human colon carcinoma variant cells selected for their differential expression of sialyl-dimeric Le(x)-antigen.
- OVX1 as a marker for early stage endometrial carcinoma.
- OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.
- OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal.
- Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology.
- Pharmacokinetics of a radioiodinated monoclonal antibody F(ab')2 fragment in a xenograft model with circulating antigen.
- Preoperative evaluation of serum CA 125, TAG 72, and CA 15-3 in patients with endometrial carcinoma.
- Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer.
- Technology evaluation: Theratope, Biomira Inc.
- The cell surface glycosphingolipids SSEA-3 and SSEA-4 are not essential for human ESC pluripotency.
- The effectiveness of ovarian cancer screening. A decision analysis model.
- The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction.
- The role of tumor markers in gynecologic oncology.
- The use of tumor markers in the management of patients with gynecologic carcinomas.
-
Keywords of People
- Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology